tetano
Editor, Senior Moderator
BioDrugs. 2012 Dec 1;26(6):425-30. doi: 10.2165/11209740-000000000-00000.
A/H5N1 Prepandemic Influenza Vaccine (Vepacel?): A Guide to Its Use.
Keating GM, Plosker GL, Lyseng-Williamson KA.
Source
Adis, Auckland, New Zealand.
Abstract
Vepacel? is a prepandemic influenza vaccine (whole virion, Vero cell-derived, inactivated) containing antigen of H5N1 strain A/Vietnam/1203/2004 and is approved for use in the EU. Clinical immunogenicity studies with the vaccine have demonstrated good functional neutralizing antibody responses against the vaccine strain (A/Vietnam/1203/2004), and cross-reactivity against H5N1 strains from other clades. In general, adverse events observed in clinical immunogenicity studies with a whole virions H5N1 vaccine (A/Vietnam/1203/2004) were similar to those reported with non-adjuvanted, inactivated, split virion seasonal influenza vaccines.
PMID:
23106407
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/23106407
A/H5N1 Prepandemic Influenza Vaccine (Vepacel?): A Guide to Its Use.
Keating GM, Plosker GL, Lyseng-Williamson KA.
Source
Adis, Auckland, New Zealand.
Abstract
Vepacel? is a prepandemic influenza vaccine (whole virion, Vero cell-derived, inactivated) containing antigen of H5N1 strain A/Vietnam/1203/2004 and is approved for use in the EU. Clinical immunogenicity studies with the vaccine have demonstrated good functional neutralizing antibody responses against the vaccine strain (A/Vietnam/1203/2004), and cross-reactivity against H5N1 strains from other clades. In general, adverse events observed in clinical immunogenicity studies with a whole virions H5N1 vaccine (A/Vietnam/1203/2004) were similar to those reported with non-adjuvanted, inactivated, split virion seasonal influenza vaccines.
PMID:
23106407
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/23106407